KRAS and metastatic colorectal cancer: The high frequency of KRAS mutations in serrated adenocarcinomas also indicates that most serrated adenocarcinomas are natively insensitive to epidermal growth factor receptor-blocking therapies, which are increasingly being used to treat metastatic colorectal cancer.33,34